Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process.
暂无分享,去创建一个
Munir Pirmohamed | Hassan Malik | Emma L. Wilkinson | M. Pirmohamed | M. Cross | M. Schwab | E. Schaeffeler | C. Goldring | D. Dickens | S. Rädisch | G. N. Chiduza | A. Giannoudis | H. Malik | R. Sison-Young | A. Nies | Matthias Schwab | Elke Schaeffeler | Christopher E Goldring | Anne T Nies | Michael J Cross | Athina Giannoudis | David Dickens | Steffen Rädisch | George N Chiduza | Rowena L Sison-Young | Emma L Wilkinson | Steffen Rädisch
[1] K. Dietz,et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. , 1998, British journal of clinical pharmacology.
[2] Emma L. Wilkinson,et al. Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability , 2016, Biology Open.
[3] Joanne Wang,et al. Selective Transport of Monoamine Neurotransmitters by Human Plasma Membrane Monoamine Transporter and Organic Cation Transporter 3 , 2010, Journal of Pharmacology and Experimental Therapeutics.
[4] Stephen A Baldwin,et al. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. , 2013, Molecular aspects of medicine.
[5] J. Wang,et al. The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition , 2016, Clinical pharmacology and therapeutics.
[6] P. Couraud,et al. ABC AND SLC TRANSPORTER EXPRESSION AND POT SUBSTRATE CHRACTERIZATION ACROSS THE HUMAN CMEC/ D3 BLOOD-BRAIN BARRIER CELL LINE , 2010 .
[7] R. Cecchelli,et al. A Simple Method for Assessing Free Brain/Free Plasma Ratios Using an In Vitro Model of the Blood Brain Barrier , 2013, PloS one.
[8] S. Kim,et al. In Vivo Tissue Pharmacokinetics of Carbon-11-Labeled Clozapine in Healthy Volunteers: A Positron Emission Tomography Study , 2015, CPT: pharmacometrics & systems pharmacology.
[9] B. Jansson,et al. In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy , 2016, Molecular Psychiatry.
[10] Christoph Hiemke,et al. How Does the Benzamide Antipsychotic Amisulpride get into the Brain?—An In Vitro Approach Comparing Amisulpride with Clozapine , 2003, Neuropsychopharmacology.
[11] G. Superti-Furga,et al. A Call for Systematic Research on Solute Carriers , 2015, Cell.
[12] W. Pardridge,et al. Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[13] Mikko Niemi,et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 , 2013, Genome Medicine.
[14] Christel A. S. Bergström,et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. , 2008, Journal of medicinal chemistry.
[15] Stanley E. Lazic,et al. Transcriptional Profiling of Human Brain Endothelial Cells Reveals Key Properties Crucial for Predictive In Vitro Blood-Brain Barrier Models , 2012, PloS one.
[16] M. Pirmohamed,et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. , 2012, Biochemical pharmacology.
[17] K. Mizuguchi,et al. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity , 2011, Pharmacogenetics and genomics.
[18] S. Summerfield,et al. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[19] Guangji Wang,et al. Prediction of human pharmacokinetics from preclinical information of rhein, an antidiabetic nephropathy drug, using a physiologically based pharmacokinetic model. , 2014, Basic & clinical pharmacology & toxicology.
[20] K. Brouwer,et al. In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.
[21] M. Pirmohamed,et al. Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol , 2017, Scientific Reports.
[22] L. Bertilsson,et al. Genetic and Clinical Factors Affecting Plasma Clozapine Concentration. , 2015, The primary care companion for CNS disorders.
[23] Lie-Chwen Lin,et al. The Drug-Drug Effects of Rhein on the Pharmacokinetics and Pharmacodynamics of Clozapine in Rat Brain Extracellular Fluid by In Vivo Microdialysis , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[24] M. Panicker,et al. Functional Selectivity in Serotonin Receptor 2A (5-HT2A) Endocytosis, Recycling, and Phosphorylation , 2013, Molecular Pharmacology.
[25] Li Di,et al. Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.
[26] Bruno Stieger,et al. Organic anion-transporting polypeptides. , 2014, Current topics in membranes.
[27] D. Keppler,et al. Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide* , 2000, The Journal of Biological Chemistry.
[28] E. Perucca,et al. Effect of Adjunctive Lamotrigine Treatment on the Plasma Concentrations of Clozapine, Risperidone and Olanzapine in Patients With Schizophrenia or Bipolar Disorder , 2006, Therapeutic drug monitoring.
[29] H. Kamimura,et al. Characterization of Human Organic Cation Transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-Mediated Transport of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small Molecule Survivin Suppressant , 2010, Drug Metabolism and Disposition.
[30] Y. Sawada,et al. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. , 2006, Drug metabolism and pharmacokinetics.
[31] W. Dubin,et al. Drug interactions affecting clozapine levels , 2015 .
[32] David J. Begley,et al. Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.
[33] Douglas B. Kell,et al. A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs , 2015 .
[34] M. Rapacz,et al. Reference genes in real-time PCR , 2013, Journal of Applied Genetics.
[35] J. Volavka,et al. Multiple-Dose Pharmacokinetics of Clozapine in Patients , 1987, Pharmaceutical Research.
[36] Joanne Wang,et al. Interaction of Organic Cations with a Newly Identified Plasma Membrane Monoamine Transporter , 2005, Molecular Pharmacology.
[37] M. Daly,et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles , 2014, Nature Communications.
[38] M Pirmohamed,et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. , 2000, Molecular pharmacology.
[39] J R Chretien,et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.
[40] Q. Al-Awqati. One hundred years of membrane permeability: does Overton still rule? , 1999, Nature Cell Biology.
[41] D. Keppler,et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[42] P. Wolf,et al. Lamotrigine therapeutic thresholds , 2008, Seizure.
[43] A. Klimke,et al. Uptake of Clozapine into HL-60 Promyelocytic Leukaemia Cells , 2002, Pharmacopsychiatry.
[44] B. Roth,et al. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo , 1999, Neuroscience.
[45] M. Wiciński,et al. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring , 2018, Current opinion in hematology.
[46] Amy E. Chadwick,et al. Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile , 2016, Archives of Toxicology.
[47] B. Pollock,et al. Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics , 2014, Journal of Translational Medicine.
[48] P. Visscher,et al. Five years of GWAS discovery. , 2012, American journal of human genetics.
[49] L. Gustavsson,et al. Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. , 2013, Journal of medicinal chemistry.
[50] Douglas B Kell,et al. What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible? , 2015, Trends in pharmacological sciences.
[51] Doris Chen,et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. , 2014, Nature chemical biology.
[52] S. Vavricka,et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver , 2002, Hepatology.
[53] Joanne Wang,et al. Identification and Characterization of a Novel Monoamine Transporter in the Human Brain* , 2004, Journal of Biological Chemistry.
[54] H. E. Meyer zu Schwabedissen,et al. LST‐3TM12 is a member of the OATP1B family and a functional transporter , 2018, Biochemical pharmacology.
[55] David S Wishart,et al. Using DrugBank for In Silico Drug Exploration and Discovery , 2016, Current protocols in bioinformatics.
[56] A. Sekine,et al. Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins , 2001, Journal of Human Genetics.
[57] D. Kell,et al. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.
[58] Joanne Wang,et al. Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine , 2007, Drug Metabolism and Disposition.
[59] O. Spigset,et al. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. , 2007, The Journal of clinical psychiatry.
[60] B. Cohen,et al. Tissue Concentrations of Clozapine and its Metabolites in the Rat , 1993, Neuropsychopharmacology.
[61] M. Pirmohamed,et al. Transport of gabapentin by LAT1 (SLC7A5). , 2013, Biochemical pharmacology.
[62] M. Pirmohamed,et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. , 2008, Blood.
[63] H. Bönisch,et al. Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.
[64] Ming Yang,et al. Quantitative determination of rhein in human plasma by liquid chromatography-negative electrospray ionization tandem mass/mass spectrometry and the application in a pharmacokinetic study. , 2012, Journal of pharmaceutical and biomedical analysis.
[65] J. Kopitz,et al. High clozapine concentrations in leukocytes in a patient who developed leukocytopenia , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[66] H. McLeod,et al. Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics , 2007, Clinical pharmacology and therapeutics.
[67] Joanne Wang,et al. Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. , 2016, Pharmacological research.
[68] Ute Hofmann,et al. Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs) , 2011, PloS one.
[69] Bruno Stieger,et al. The SLCO (former SLC21) superfamily of transporters. , 2013, Molecular aspects of medicine.
[70] F. Behar-Cohen,et al. Blood–brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P‐glycoprotein on a novel verapamil influx carrier , 2016, British journal of pharmacology.
[71] D. Keppler,et al. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.
[72] M. Schwab,et al. Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors , 2015, The Pharmacogenomics Journal.
[73] Euan J. Rodger,et al. Genome-wide DNA methylation map of human neutrophils reveals widespread inter-individual epigenetic variation , 2015, Scientific Reports.